CoChat

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Published version of a preprint

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Abstract

Alterations in EGFR, KRAS, and ALK are oncogenic drivers in lung cancer, but how oncogenic signaling influences immunity in the tumor microenvironment is just beginning to be understood. Immunosuppression likely contributes to lung cancer, because drugs that inhibit immune checkpoints like PD-1 and PD-L1 have clinical benefit. Here, we show that activation of the AKT–mTOR pathway tightly regulates PD-L1 expression in vitro and in vivo. Both oncogenic and IFNγ-mediated induction of PD-L1 was dependent on mTOR. In human lung adenocarcinomas and squamous cell carcinomas, membranous expression of PD-L1 was significantly associated with mTOR activation. These data suggest that oncogenic activation of the AKT–mTOR pathway promotes immune escape by driving expression of PD-L1, which was confirmed in syngeneic and genetically engineered mouse models of lung cancer where an mTOR inhibitor combined with a PD-1 antibody decreased tumor growth, increased tumor-infiltrating T cells, and decreased regulatory T cells. Cancer Res; 76(2); 227–38. ©2015 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-3362

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

See all 811

Metadata

Authors
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., Liu, L. N., Gills, J. J., & Dennis, P. A.
Affiliations
  • Johns Hopkins University (US)
  • National Institutes of Health (US)
  • Amplimmune (United States) (US)
Venue
Cancer Research
Published
2016-01-14
Volume
76
Issue
2
Pages
227-238
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2196159484
Cited by
785
References
52
Citations by year
2026: 32 · 2025: 73 · 2024: 69 · 2023: 80 · 2022: 89 · 2021: 98 · 2020: 102 · 2019: 75 · 2018: 74 · 2017: 61 · 2016: 31
FWCI
24.17
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P30CA006973)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-L1 expression, Akt/mTOR signaling, non-small cell lung cancer, tumor immune microenvironment, immune evasion, mTOR inhibition, anti-PD-1, interferon-gamma, lung adenocarcinoma, lung squamous cell carcinoma, regulatory T cells, tumor-infiltrating T cells, oncogenic signaling
MeSH terms
Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Transfection, Oncogene Protein v-akt, Mice, TOR Serine-Threonine Kinases, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-3362
The paper
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., Liu, L. N., Gills, J. J., & Dennis, P. A. (2016). Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-3362

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.